Revolution Medicines Inc
RVMD
Company Profile
Business description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Contact
700 Saginaw Drive
Redwood CityCA94063
USAT: +1 650 481-6801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
616
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,868.40 | 46.40 | 0.59% |
| DAX 40 | 24,482.99 | 112.06 | 0.46% |
| Dow JONES (US) | 44,484.49 | 229.71 | 0.52% |
| FTSE 100 | 8,991.50 | 18.86 | 0.21% |
| HKSE | 24,800.07 | 301.12 | 1.23% |
| NASDAQ | 20,885.65 | 155.16 | 0.75% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,297.36 | 33.66 | 0.54% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |